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Abstract
The distinction between pseudo-Cushing’s states (PCS) and Cushing’s syndrome (CS) 
poses a significant clinical challenge even for expert endocrinologists. A patient’s clinical 
history can sometimes help to distinguish between them (as in the case of alcoholic 
individuals), but the overlap in clinical and laboratory findings makes it difficult to arrive at 
a definitive diagnosis. We aim to describe the most common situations that can give rise 
to a condition resembling overt endogenous hypercortisolism and try to answer questions 
that physicians often face in clinical practice. It is important to know the relative prevalence 
of these different situations, bearing in mind that most of the conditions generating PCS 
are relatively common (such as metabolic syndrome and polycystic ovary syndrome), 
while CS is rare in the general population. Physicians should consider CS in the presence 
of additional features. Appropriate treatment of underlying conditions is essential as it 
can reverse the hormonal abnormalities associated with PCS. Close surveillance and a 
thorough assessment of a patient’s hormone status will ultimately orient the diagnosis and 
treatment options over time.
Introduction
Physiological activation of the hypothalamic-
pituitary-adrenal (HPA) axis can be found in several 
situations, such as major surgery, severe illness, 
intensive physical exercise, and prolonged fasting 
leading to improve the ability of the organism to 
survival (1).
Some common endocrine diseases including obesity, 
polycystic ovary syndrome (PCOS), poorly controlled 
diabetes mellitus (DM), chronic alcoholism, and 
psychiatric disorders may also coincide with HPA axis 
activation (2). Under such conditions, there may be 
some clinical signs of hypercortisolism, which may be 
temporary or more persistent, giving rise to what is called 
pseudo-Cushing’s syndrome (PCS).
The differential diagnosis of PCS and Cushing’s 
syndrome (CS) is still a major clinical challenge even for 
expert endocrinologists. Study findings are inconsistent 
and no consensus on the correct diagnosis has been 
reached as yet. Standard adrenal steroid measurements 
often overlap in cases of PCS and CS, and several drugs 
affect the dynamic test results.
By describing and discussing a clinical case, this 
review attempts to answer some common questions that 
physicians may face in the clinical practice.
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Clinical case
A 26-year-old female was referred to a tertiary endocrine 
center for suspected endogenous hypercortisolism. 
She had a long-standing diagnosis of type-1 DM and a 
psychiatric condition characterized by depression and 
anxiety that was treated with fluoxetine.
She had experienced oligomenorrhea since her first 
menstrual cycle at 14 years of age. At 20 years of age, she 
was diagnosed with polycystic ovarian syndrome (PCOS) 
based on her oligomenorrhea, hyperandrogenism, and 
micropolycystic ovaries found on pelvic ultrasound. 
She began taking oral estro-progestin therapy and was 
continuing to do so at the time of our assessment. During 
a hospitalization for a suspected bowel obstruction, 
she had revealed some clinical signs suggestive 
of hypercortisolism (central adipose distribution, 
hirsutism, and round face, but no evidence of proximal 
myopathy or reddish purple striae). She was overweight 
(BMI 28 kg/m2, with a waist circumference of 92 cm), with 
high blood pressure (140/90 mmHg).
Laboratory findings revealed high levels of serum 
cortisol at 08:00 h (29 µg/dL; n.v. 5–25), and high urinary 
free cortisol (UFC) (280 µg/24 h; n.v. 36–137), while ACTH 
levels at 08:00 h were in the normal range (26 pg/mL; 
n.v. 10–50). The patient’s diabetes was poorly controlled 
(HbA1c 8%).
The suspected CS was confirmed by the lack of 
cortisol suppression after 1 mg dexamethasone (10 µg/dL, 
n.v. <1.8) and the absence of a cortisol circadian 
rhythm (midnight serum cortisol, MserC, 12 µg/dL; 
n.v. <7.5).
Which clinical features are the strongest 
indicators of CS?
Easy bruising, facial plethora, proximal myopathy, 
and cutaneous striae (reddish purple 1 cm wide) are 
reportedly the clinical features that best discriminate 
CS (3). These signs were all lacking in our patient, 
but we knew that most of these features have a low 
sensitivity. The patient had a round face and was 
overweight, with central adipose distribution and 
hirsutism, features that are commonly seen in CS 
patients, but of lower discriminatory value. On the 
other hand, these signs are indistinguishable from 
patients with PCOS, which is a common disease 
among women of reproductive age (4), whereas CS is 
more rare (5).
Which is the first-line approach for patients 
with suspected CS?
The Endocrine Society guidelines recommend using the 
1 mg dexamethasone suppression test (1-mg DST), late-
night salivary cortisol (LNSC; two measurements), or UFC 
(two measurements) for first-line screening purposes. 
Then, additional methods such as a longer, low-dose DST 
(2 mg for 48 h) and midnight serum cortisol, may be 
considered (3, 6).
LNSC is increasingly used nowadays (7), based on the 
assumption that most patients with CS lose their normal 
cortisol diurnal pattern and have persistently elevated 
cortisol levels throughout the day, whereas PCS patients 
retain their normal secretion rhythm, albeit on a higher 
setting, with a cortisol nadir at midnight (8). Although 
further studies are needed to confirm these findings, 
LNSC seems to perform better than 1-mg DST or UFC in 
distinguishing PCS from CS. Unlike the midnight serum 
cortisol measurement that requires inpatient admission, 
saliva collection is easy to perform in an outpatient 
setting. However, LNSC is not widely used in the clinical 
practice and the studies reported have not set a clearly 
defined cut-off value to be used in the diagnosis of CS. 
Thus, each center should determine its own cut-off value 
based on the method adopted for LNSC measurement.
UFC provides an integrated assessment of cortisol 
secretion over a 24-h period. It measures the cortisol that 
is not bound to corticosteroid-binding globulin (CBG), 
which is filtered by the kidney unchanged. A falsely low 
UFC can occur when creatinine clearance falls less than 
60 mL/min (3). It is important that patients provide 
complete urine collections with appropriate total volumes 
(this may require an adequate patient education) and the 
concomitant measurement of urinary creatinine levels.
Which aspects should be considered before 
screening patients with suspected CS?
When performing cortisol assays, it is important to 
consider analytical bias. There are two ways to measure 
cortisol: immunoassays, for example, RIA, ELISA, or 
automated chemiluminescence (ECLIA) and liquid 
chromatography-tandem mass spectrometry (LC–MS/MS). 
Antibody-based immunoassays can be affected by cross-
reactivity (especially cortisone, which has a structure 
similar to that of cortisol) and synthetic glucocorticoids 
(9). In fact, cortisol is converted into inactive cortisone 
by 11β-hydroxysteroid dehydrogenase (11β-HSD) type 2. 
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Structure-based assays like LC–MS/MS do not pose this 
problem and allow for various glucocorticoids and 
metabolites to be separated, and they are probably 
the most accurate methods for assessing cortisol and 
cortisone levels (9).
The concomitant use of commonly prescribed 
therapies may alter dexamethasone metabolism, 
interfering with its use in a suppression test. Some 
types of medication can interfere with the CYP3A4 
enzyme system, either accelerating (i.e. phenobarbital, 
phenytoin, carbamazepine, pioglitazone, primidone, 
rifampin, rifapentine, and ethosuximide) or impairing (i.e. 
aprepitant, itraconazole, ritonavir, fluoxetine, diltiazem, 
and cimetidine) dexamethasone metabolism (3).
Measuring dexamethasone levels could help to identify 
any abnormal clearance. A recent study has used a rapid and 
sensitive LC–MS/MS assay for measuring dexamethasone 
levels in a cohort of normal healthy postmenopausal 
women. Applying a serum dexamethasone cut-off 
of >3.3 nmol/L was associated with a serum cortisol 
 ≤50 nmol/L in 84/95 of the individuals (10). However, 
serum dexamethasone levels are not measured routinely 
in international clinical practice.
Oral estrogens can increase CBG levels and 
consequently raise total cortisol levels, again potentially 
generating abnormal test results (11, 12, 13). 
Oral estrogens should be withdrawn for at least 6 weeks 
before testing or retesting patients with suspected CS (3).
Our patient was taking fluoxetine, which inhibit 
the CYP3A4 system leading to impaired dexamethasone 
metabolism, and oral estrogens that can influence the 
result of any test.
How can patients’ concomitant conditions 
influence the diagnosis of PCS?
Neuropsychiatric disorders
HPA axis hyperactivity is a frequent finding in patients 
with major depressive disorder (MDD) (14). Overall, about 
20–30% of patients with MDD reveal hypercortisolemia 
(15, 16). Depressed male patients appear to have a more 
reliable cortisol hypersecretion, raising the issue of sex 
differences in HPA axis hyperactivity in depressed patients 
(16, 17) (Table 1).
The post-awakening surge in cortisol is known to be 
accentuated in individuals at risk of MDD (18), and about 
one in two patients with MDD have high evening cortisol 
levels indicative of disrupted diurnal cortisol rhythms 
(14, 19). The defect that induces HPA axis overactivity seems 
to be localized in the upper part of the hypothalamus, 
and there have been reports of increased levels of 
Table 1 Most common causes of PCS and main associated abnormalities of the hypothalamus-pituitary adrenal-axis (HPA) 
reported.
Causes of PCS Abnormalities of HPA axis reported
Neuropsychiatric disorders Accentuated post-awakening surge in cortisol
High evening cortisol levels in some patients
Increased or decreased CRH levels
Resistance to the feedback action of DST on HPA axis activity
Reduced activity of cortisol-deactivating enzymes (5-α-reductase and 11β-HSD type 2)
Polycystic ovary syndrome Mildly elevated UFC levels in ~50% of patients
Decreased corticosteroid-binding globulin
Increased androstenedione, total and free testosterone levels
Reduced sex hormone-binding globulin 
Obesity Increased cortisol reactivity to physical and psychosocial stressors
Preserved pituitary sensitivity to feedback inhibition by DST
Increased 5 α-reductase type 1 activity in the liver
Upregulation of cortisol output due to great expression of 11β-HSD type 1
Alcohol abuse Stimulated CRH production with increased ACTH levels
Higher fasting cortisol at 08.30 h
Impaired cortisol clearance due to hepatic dysfunction
Abnormal cortisol suppression to 1-mg DST
Eating disorders Reduced cortisol clearance
Changes in the affinity of cortisol to CBG
Resistance to the action of glucocorticoids
High CRH levels with normal ACTH
Preserved circadian rhythm of cortisol
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corticotropin-releasing hormone (CRH) in depression, as 
well as a significant decrease in this hormone in atypical 
depression (20).
A proportion of patients with MDD also have a greater 
resistance to the feedback action of glucocorticoids on HPA 
axis activity (20, 21) and this weaker sensitivity is often 
restored by effective psychopharmacological therapy (22).
Data regarding the pulsatile release of cortisol 
and ACTH in depressed patients are ambiguous, with 
reports of increased (23), unchanged (24), or reduced 
(25) frequencies. Analyzing these conflicting findings 
of different studies suggests that the prevalence of 
abnormalities in cortisol and ACTH levels might depend 
partly on how they are measured and the type of depressed 
patients examined. Many such patients nonetheless reveal 
one or more abnormal test among an abnormal cortisol 
suppression with the 1-mg DST or higher night-time and 
urinary cortisol levels.
A reduced activity of the intracellular cortisol-
deactivating enzymes (5-α-reductase and 11β-HSD type 
2) has been demonstrated in depressed patients too, and 
this may raise the cortisol bio-availability within tissues 
(25). Certain therapies for depression may improve 
5-α-reductase activity without affecting 11β-HSD type 
2 activity, and this would explain why the disrupted 
glucocorticoid metabolism may be only partly improved 
by antidepressants (25).
Finally, it has been claimed that cortisol dysfunction 
in patients with MDD could be one of the factors involved 
in their higher risk of metabolic syndrome and type 2 DM 
(26) and their higher cardiovascular mortality (27, 28).
Polycystic ovary syndrome (PCOS)
Anovulation, oligo-amenorrhea, hirsutism, acne, insulin 
resistance, DM, overweight/obesity, and hypertension 
may be seen to a variable degree in PCOS and CS patients. 
There is a difference in their prevalence, however, 
PCOS is quite common, occurring in 6.6% of women of 
reproductive age (4), whereas CS is a rare condition with 
an incidence of 0.7–2.6 cases per million population 
yearly (5). The two conditions may overlap in some 
young women. In a retrospective review of patients of 
reproductive age with a confirmed diagnosis of CS, one in 
two were initially diagnosed with isolated PCOS (29). The 
patients had nearly identical clinical profiles, except that 
hirsutism and menstrual irregularities were more common 
in those initially diagnosed with PCOS. These findings are 
of interest because treatment for PCOS did not solve the 
hypercortisolism, and the oral estrogens generally used to 
treat PCOS may be deleterious in CS patients due to their 
high thrombotic risk. A delay in the diagnosis of CS can 
have important clinical consequences too.
On the other hand, a prospective study conducted 
on premenopausal women with proven CS found signs 
and symptoms of hyperandrogenism in all patients, 
menstrual irregularities in 70%, and a polycystic ovarian 
morphology in 46% (30). This report confirms that a 
PCOS phenotype is common in CS women, particularly 
among those with moderately high glucocorticoid levels 
(31). When circulating cortisol exceeds critical levels, 
there is an inhibitory effect on the hypothalamic control 
of gonadotropin release and ovarian volumes seem to be 
preserved.
Pall et al. (32) hypothesized that total testosterone (TT) 
levels could be lower in patients with mild CS compared 
to women with PCOS. They found that the optimal cut-
off for TT was 1.39 nmol/L, yielding a sensitivity of 95% 
and a specificity of 70%. The evaluation was done with a 
well-validated assay, but most commercial assays lack of 
accuracy and precision when measuring testosterone in 
women. Moreover, only subjects identified with mild CS 
of pituitary origin were included in the study and so the 
criteria cannot be applied to patients with other forms of 
CS. Thus, larger studies are needed to confirm these data.
It may be reasonable to screen women with PCOS for 
hypercortisolism. The 1-mg DST has a high specificity and 
diagnostic accuracy. The test maintained its sensitivity 
using a lower cut-off, and this is important in a screening 
setting (33). Measuring midnight plasma cortisol levels is 
a highly sensitive method too, while caution is needed in 
interpreting mildly elevated UFC levels in women with 
PCOS. In both, normal weight and obese patients with 
PCOS, UFC may exceed the upper limit of the normal 
range in about 50% of the patients (34).
Diabetes mellitus, obesity and metabolic syndrome
Although limited data are available on the prevalence 
of CS in patients with DM, the diagnosis should be 
considered particularly in cases with a number of highly 
discriminatory signs or symptoms.
After screening a large number of patients attending 
diabetes clinics in an outpatient setting and in conditions 
of standard clinical practice, Terzolo et  al. (35) found a 
frequency of previously unsuspected CS of 0.7% (in the 
largest series published so far). Its frequency was higher 
(5.1%) among patients whose diabetes and hypertension 
were poorly controlled despite intensive treatment. In a 
previous series, Catargi et al. (36) found a definitive CS in 
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2% of overweight, type-2 DM patients referred for poor 
metabolic control. In both studies, a first screening was 
performed with the 1-mg DST.
Although these results do not support a wide-
scale screening for CS in type-2 DM patients, a case-
finding approach is warranted for selected patients with 
uncontrolled glycemia or resistant hypertension.
Obesity is an ongoing pandemic condition, the 
prevalence of which is continuing to rise worldwide.
The association between cortisol and obesity has 
been extensively studied and it appears that obesity is 
often, but not always, related to a hyperresponsive HPA 
axis (37). The studies indicate that cortisol secretion is 
often elevated but that circulatory concentrations are 
normal or low probably due to substantial changes in 
peripheral metabolism of cortisol (38). These changes 
are tissue specific, with increased inactivation of cortisol 
in the liver (by increased 5α-reductase type 1 activity 
that metabolizes cortisol to its tetrahydro derivatives) 
and increased regeneration of cortisol in adipose tissue 
(39). The increased inactivation of cortisol in the liver 
may be responsible for the compensatory activation of 
the HPA axis.
Women with abdominal obesity phenotype have an 
exaggerated ACTH and cortisol response to combined 
CRH/AVP (corticotropin-releasing hormone/arginine 
vasopressin) stimulation (40). Higher than normal UFC 
values have been found in women with abdominal obesity 
(41, 42). However, these data were not confirmed when 
anxiety and depression were excluded (40), suggesting 
that confounding factors are capable of altering the HPA 
axis in obesity.
Increased cortisol reactivity observed after both, 
physical and psychosocial acute stressors, seems to be 
the one parameter where results are consistent in obese 
subjects (40, 41, 43).
Subtle differences in pituitary feedback sensitivity have 
been found in the cortisol response to dexamethasone 
test. Abdominal obesity seems to be associated with poorer 
response using 0.5 mg of dexamethasone overnight (43). 
However, Pasquali et al. (44) demonstrated that pituitary 
sensitivity to dexamethasone administration is preserved 
in obese subjects of both sexes even at low dosages.
Abraham et  al. (45) analyzed the associations 
between three parameters of activity of the HPA axis 
(nadir of salivary cortisol levels, UFC, and the 1 mg 
DST) and weight, metabolic syndrome and psychosocial 
stress in a large number of overweight and obese 
individuals with at least two features of CS. Apart 
from a weak correlation of salivary cortisol in men, 
they found no relationship between waist circumference 
and any cortisol parameter. Their findings do not support 
a strong link between systemic cortisol and obesity or 
metabolic syndrome.
Many of the inconsistencies found in the different 
studies may be associated to various cortisol measurements 
methodology and different study designs.
Particular attention has been posed to the activity 
of the 11β-HSD type 1 localized in different tissues. 
This is a microsomal enzyme which converts inactive 
cortisone to active cortisol, thus regulating intracellular 
cortisol access to glucocorticoid receptor. Although 
data are inconsistent, there is a suggestion that local 
glucocorticoids action may be amplified by upregulated 
activity of 11β-HSD type 1 in visceral and hepatic tissue 
of obese subjects (46, 47). Omental fat can generate active 
cortisol from inactive cortisone via 11β-HSD type 1, 
amplify glucocorticoid receptor activation, and promote 
pre-adipocyte differentiation and adipocyte hypertrophy, 
inducing adiposity (46). The increased expression of 
11β-HSD type 1 in omental adipose tissue seems to support 
its involvement in severe obesity (48).
However, a number of respective studies have 
been performed in animal models and in humans with 
controversial results (49) probably associated to the 
differentially expression and activity of 11β-HSD type 1 in 
different species and tissues.
Several inhibitors of 11-βHSD type 1 have consequently 
been tested in animals, obtaining an improvement in 
glucose control and lipid profile (47, 50).
Even though being controversially discussed, the role 
of 11β-HSD type 1 in the pathogenesis of the metabolic 
syndrome must be further considered.
Which other situations can be associated 
with PCS?
Alcohol abuse
The first report on patients with symptoms mimicking CS 
caused by alcoholism appeared at the end of the 1970s 
(51). Studies conducted in mice demonstrated that alcohol 
can stimulate CRH production via the hypothalamic 
paraventricular nucleus, with consequent HPA axis 
activation and increased levels of ACTH (52). Induction of 
the enzyme 11-βHSD type 1 was demonstrated in patients 
with alcoholic liver disease, coinciding with an increased 
cortisol production or an impaired cortisol clearance due 
to hepatic dysfunction.
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Although the severe classical phenotype is not 
difficult to diagnose, chronic alcoholism can induce 
a phenotype that largely overlaps with CS. Several case 
reports have provided details emerging from the physical 
examination of patients with symptoms compatible with 
CS, which eventually proved to be the result of alcohol 
addiction: 87% had a moon face, 81% had muscle 
weakness or tiredness, 75% had truncal obesity, 69% had 
hypertension, and 12% had cutaneous striae (53).
Coiro et  al. (54) measured cortisol in ten women 
with alcohol-induced PCS and found a higher fasting 
cortisol at 08.30 h than in controls. Frias et  al. (55) 
examined adolescents during episodes of acute alcohol 
intoxication, finding elevated cortisol levels, which was 
more pronounced in females. Studying the presence of 
cortisol in the hair, Stalder et al. (56) detected higher levels 
in individuals who had recently stopped drinking alcohol 
than in either controls or individuals who had abstained 
for a longer period. When heavy drinkers were compared 
with light drinkers, the former had higher salivary cortisol 
levels on awakening and 30 min afterwards (57). An 
insufficient cortisol suppression in the 1-mg DST was also 
reported in several studies (53).
Interestingly, case reports invariably indicated that 
alcohol withdrawal led to the disappearance of patients’ 
symptoms and biochemical disruptions (58).
A detailed clinical history is crucially important in 
patients with CS, and alcoholic patients should undergo a 
repeat of their clinical and biochemical work-up after they 
have stopped drinking alcohol for at least 1 month (53).
Eating disorders
Anorexia nervosa is a psychiatric disorder characterized 
by an extreme restriction of food intake despite being 
underweight, with a refusal to maintain body weight 
above the minimum threshold of normality. It can 
severely alter the patient’s eating behavior and is 
associated with mortality rates of up to 22%. Patients, 
usually women, have endocrine abnormalities such as 
amenorrhea, an impaired body temperature regulation, 
and hypercortisolism, probably linked to chronic fasting-
related stress. HPA axis dysregulation may persist even 
after weight recovery, however, suggesting that it may be 
involved in the pathogenesis of the disease itself (59).
Hypercortisolism has been amply documented in 
young women with anorexia nervosa. Many mechanisms 
have been hypothesized, including a reduced cortisol 
clearance, changes in the affinity of cortisol for CBG, or in 
the concentration of glucocorticoid receptor. In particular, 
resistance to the action of glucocorticoids may explain 
not only the hypercortisolism but also the lack of clinical 
signs of cortisol excess in such underweight women.
The mechanisms behind hypercortisolism in anorexia 
nervosa appear to differ from those associated with MDD, 
with CRH having a more important role in stimulating the 
HPA axis in the case of anorexia. The powerful anorectic 
effect of CRH could contribute to the severe weight loss 
observed in this disorder (60): the levels of CRH are 
higher than normal, while those of ACTH are normal, 
and the latter has a reduced response to stimulation with 
CRH, whereas adrenal cortisol production increases after 
stimulation with ACTH. Despite the changes in the HPA 
axis, the circadian rhythm of cortisol generally seems to 
be preserved in anorexia patients, although conflicting 
data emerged from some studies (61).
The functional cortisol excess seen in anorexia and 
bulimia can have numerous negative effects. Some data 
point to its role in promoting the psychological and 
cognitive changes observed in patients with anorexia. A 
relationship has also emerged between the lack of cortisol 
response to 1-mg DST suppression and the presence and 
severity of depressive symptoms associated with eating 
disorders.
Some authors have also underscored the possible role 
of cortisol in the onset of attention deficit, especially in 
anorexia. Nutritional deficiencies and hypercortisolism 
may also promote bone loss in such patients, and the 
influence of hypercortisolism on other pituitary axes 
(the gonadotropic, growth hormone, and thyroid) may 
be responsible for oligomenorrhea-amenorrhea and 
a reduced TSH secretion despite low levels of T3 and 
T4. Finally, although the hypercortisolism associated 
with anorexia nervosa may not lead to a build-up of 
fat tissue due to the lack of substrates, it can affect the 
disproportionate accumulation of central adiposity after 
recovery from illness.
Getting back to our patient
As regards her diagnosis, our patient had several conditions 
(a neuropsychiatric disorder, overweight, and PCOS) that 
can be associated with PCS, and most of them could be 
secondary to a genuine endogenous hypercortisolism. 
Another aspect to emphasize concerns the treatments 
she was taking (oral contraceptives and antidepressants) 
that may have interfered with her hormone assessment 
(i.e. serum cortisol midnight and in the 1-mg DST). When 
she was retested again after discontinuing these drugs, 
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she still had mildly increased UFC levels (170 µg/24 h; n.v. 
36–137), with normal serum cortisol levels 2 days after a 
2-mg DST (1.2 µg/L (n.v. <1.8)). LNSC was measured twice 
using the RIA method, producing different results (2.0 
and 3.6 nmol/L n.v. 0.5–2.6).
With these results, mild CS still could not be 
ruled out.
What more can be done to exclude or 
confirm CS?
Second-line tests
Midnight serum cortisol (MserC)
A single MserC measurement using a cut-off of 207 nmol/L 
(7.5 µg/dL) was reportedly able to discriminate CS from 
PCS with a 96% sensitivity and 100% specificity (62). This 
was confirmed in further studies (63, 64) using higher 
cut-offs of 242 nmol/L; 8.8 µg/dL in wakeful patients (51) 
and <256 nmol/L (9.3 µg/dL) in all patients with PCS (65). 
In one study (63), a midnight:morning cortisol ratio of 
0.67 also seemed to discriminate well between cases of CS 
and PCS (Table 2), but this test involves hospitalizing the 
patient and may produce false-negative results in patients 
with mild or quiescent CS.
Dexamethasone-suppressed corticotropin-releasing 
hormone stimulation test (Dex–CRH)
This combined test involves 2 days of dexamethasone 
suppression followed by CRH stimulation. It was first 
introduced in 1993, based on the observation that 
patients with PCS are thought to have a decreased ACTH 
response to exogenous CRH stimulation, while the ability 
to suppress cortisol after exogenous administration 
of dexamethasone persists (65). This test has shown a 
variable performance in different studies, however. The 
first study reported an excellent discrimination between 
CS and PCS patients when serum cortisol concentrations 
measured 15 min after administering CRH were higher 
than 38 nmol/L (1.4 µg/dL) (65). But these findings were 
not confirmed in later studies (64, 66) in which the test’s 
weaker diagnostic performance led to the proposal of new 
cutoffs for cortisol 15 min after administering CRH. When 
plasma ACTH was analyzed in the same population, 
the best diagnostic performance was obtained with an 
ACTH concentration higher than 3.5 pmol/L (16 pg/mL) 
15 min after administering CRH (64). Different thresholds 
for ACTH and cortisol response proposed in other studies 
reportedly achieved different sensitivity and specificity 
levels (67) (Table 2).
Differences in the reliability of the Dex–CRH test 
emerging from the above-mentioned studies may be due 
to the use of different test protocols, ovine as opposed 
to human CRH preparations, doses of 1 μg/kg or 100 μg, 
different cortisol and ACTH assays (especially as regards 
measurements in the low range), and patients’ characteristics 
(degree of hypercortisolism, adrenal vs pituitary CS).
Low-dose dexamethasone suppression test (LDDST)
This test which involved 2 days of dexamethasone 
suppression was found to perform reasonably well. In two 
previous studies, the diagnostic accuracy of the Dex–CRH 
test did not differ significantly from that of the standard 
LDDST when cortisol cut-offs of 50 nmol/L (1.8 µg/dL) 
(66) or 55 nmol/L (2.0 µg/dL) (64) were used, though 
another study did not confirm as much (63).
CRH stimulation test
This test is generally used to differentiate between ACTH-
dependent CS forms (68). Its low diagnostic accuracy 
when used alone to discriminate between patients with 
Cushing’s disease (CD) and those with PCS has prevented 
its use for this purpose. Arnaldi et  al. (69) recently 
examined whether applying novel criteria would enable 
the test to distinguish CD from PCS and from controls 
(CT). The authors suggested two separate combinations 
of parameters, each capable of diagnosing CD: (i.) basal 
serum cortisol >331 nmol/L (12 µg/dL) and peak plasma 
ACTH >12 pmol/L (54 pg/mL) or (ii.) peak serum cortisol 
>580 nmol/L (21 µg/dL) and peak plasma ACTH >10 
pmol/L (45 pg/mL). These combinations yielded a greater 
diagnostic accuracy.
Desmopressin stimulation test (DDAVP)
DDAVP usually elicits a marked rise in plasma ACTH and 
serum cortisol in most CD patients, but not in cases of 
PCS or healthy individuals (70, 71).
It was previously claimed that a rise in plasma ACTH 
of at least 6 pmol/L within 30 min after DDAVP injection 
(∆-ACTH) was the most effective diagnostic criterion for 
distinguishing CD from PCS patients (70).
Rollin et al. (72) found that a peak ACTH concentration 
of 15.8 pmol/L or an absolute increment of ACTH of 8.1 
pmol/L over baseline could be used to correctly diagnose 
93 or 92% of the patients, respectively.
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To improve the diagnostic performance of the DDAVP 
test, Tirabassi et  al. (73) proposed a new combination 
of parameters consisting of simultaneous basal serum 
cortisol and ∆-ACTH levels: they found that a diagnosis of 
CD could be excluded for patients who were positive for 
one or neither of these parameters.
Combined assessment of second-line tests
Only a few studies have compared multiple tests in the 
same study population. Alwani et al. (63) found that the 
Dex–CRH test and LNSC or MserC measurements achieved 
a high diagnostic accuracy in distinguishing between 
true CD and PCS. The results of the different tests were 
concordant in most patients, and combining the tests did 
not improve the diagnostic yield. The authors suggested 
using LNSC as the first choice, with each diagnostic center 
validating the diagnostic threshold. Other authors (64) 
recommended using the LDDST and MserC measurement 
at the start due to a low diagnostic performance of the 
Dex–CRH.
Tirabassi et  al. (74) reported that the stimulation 
with human CRH and DDAVP tests showed an 
excellent diagnostic performance (sensitivity 96.6%, 
specificity 100% for both). These tests showed a better 
agreement than those resulting from all other possible 
combinations of the other tests considered (UFC, 
1-mg DST and serum cortisol circadian rhythm) in the 
same population of patients with CD or PCS. Using 
new interpretation criteria based on the simultaneous 
analysis of ACTH and cortisol (69, 73), the authors 
suggested using the human CRH or the DDAVP test, 
with no particular preference for either, and using both 
tests only in particular cases.
Back to our patient
The CRH test was performed after pre-treatment with 2 mg 
dexamethasone for 48 h (cortisol 0.9 µg/dL to 1 µg/dL 
at 15 min) followed by a DDAVP test (baseline cortisol: 
19 µg/dL response: 21 µg/dL; ACTH raised from 17 to 
20 pg/mL). The result of both tests was suggestive of PCS. 
Thus, the persistence of a mildly increased UFC level was 
judged to be due to inaccuracy of the assay method available.
The patient’s follow-up, implementing lifestyle 
modifications for weight loss, showed a mild regression of 
the clinical signs of hypercortisolism, thereby reinforcing 
the diagnosis of PCS (in a case of real CS, they would have 
been expected to progress).
Summary and a suggested approach
Clinical situations involving HPA axis activation giving 
rise to a so-called PCS remain a major diagnostic challenge 
for endocrinologists.
Patients may present with obesity, DM, depression, 
and PCOS that are frequent in the general population. 
At diagnosis, the patients will often have already 
consulted several specialists (gynecologists, psychiatrists, 
and internists) and may have been given different 
treatments that could interfere with their laboratory 
test results or confer an additional risk for patients with 
an occult CS.
An accurate clinical examination is needed to 
identify any features that might help to discriminate 
cases of CS, but such signs might not be apparent in mild 
hypercortisolism, making its diagnosis more difficult.
An accurate treatment of any condition that 
may lead to a suspected PCS is important because it 
can reverse the related hormone abnormalities. We 
encourage physicians to consider CS particularly if 
the patient has more than one feature of the disorder 
or a poor control of the single situation despite 
maximal therapy.
The choice of the optimal screening test in a high-
risk population relies on an expert understanding of the 
diagnostic performance of the various tests in different 
clinical settings. Although LC–MS/MS is probably the 
most accurate method for assessing UFC levels, have 
not achieved widespread use in routine clinical practice, 
and steroid cross-reactivity remains an issue when 
immunoassays are used to measure serum and urinary 
cortisol levels. LNSC needs to be further validated for 
use in this setting, demonstrating its accuracy in the 
differential diagnosis of PCS and CS.
Regarding the Dex–CRH test and/or the easier and less 
expensive DDAVP test, there is still debate on the optimal 
cut-off values for each of these tests in different clinical 
settings (obesity, MDD, and alcoholism), and none of 
them has become the gold standard for differentiating CS 
from PCS.
When a diagnosis is unreliable, we suggest treating 
the associated conditions and adopting a close follow-up, 
because the hypercortisolism associated with CS may 
progress, and the condition might consequently be 
diagnosed at a later date.
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